LENZ Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US52635N1037
USD
11.89
0.3 (2.59%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
LENZ Therapeutics, Inc.

Why is LENZ Therapeutics, Inc. ?

1
Flat results in Sep 25
  • OPERATING PROFIT(Q) Lowest at USD -18.76 MM
  • PRE-TAX PROFIT(Q) Lowest at USD -16.7 MM
  • NET PROFIT(Q) Lowest at USD -16.7 MM
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -49.38%, its profits have fallen by -4.8%
3
Underperformed the market in the last 1 year
  • Even though the market (S&P 500) has generated returns of 12.95% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -49.38% returns
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Icon
No Data Found
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
107.39%
EBIT Growth (5y)
-10.65%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
94.91%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.02
EV to EBIT
-13.34
EV to EBITDA
-13.36
EV to Capital Employed
-296.66
EV to Sales
165.30
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-25.39%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company
NET PROFIT(HY)

Higher at USD -31.61 MM

RAW MATERIAL COST(Y)

Fallen by -9,900% (YoY

NET SALES(9M)

Higher at USD 17.5 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 0.43 times

-12What is not working for the Company
OPERATING PROFIT(Q)

Lowest at USD -18.76 MM

PRE-TAX PROFIT(Q)

Lowest at USD -16.7 MM

NET PROFIT(Q)

Lowest at USD -16.7 MM

EPS(Q)

Lowest at USD -0.59

Here's what is working for LENZ Therapeutics, Inc.

Net Sales
At USD 17.5 MM has Grown at inf%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (USD MM)

Inventory Turnover Ratio
Highest at 0.43 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Net Sales
Higher at USD 17.5 MM
than preceding 12 month period ended Sep 2025
MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months

Net Sales (USD MM)

Raw Material Cost
Fallen by -9,900% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for LENZ Therapeutics, Inc.

Operating Profit
Lowest at USD -18.76 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit
Lowest at USD -16.7 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Pre-Tax Profit
At USD -16.7 MM has Fallen at -28.72%
over average net sales of the previous four periods of USD -12.97 MM
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -16.7 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

Net Profit
At USD -16.7 MM has Fallen at -27.49%
over average net sales of the previous four periods of USD -13.1 MM
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

EPS
Lowest at USD -0.59
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)